Celecoxib Attenuates Traumatic Myositis Ossificans by Decreasing Tissue BMP-4 Expression and Serum Levels of IL-2, IL-6, and TNF-α
International Journal of Pharmacology · 04.06.2026 · 22 (3)
DOI: 10.31083/ijp47662 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmacology, online erschienen am 04.06.2026. Verfasst von Mingzhong Liu und 4 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Project of Quanzhou Science & Technology Bureau, Startup Fund for scientific research, Fujian Medical University, Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
Background and Objective: Traumatic myositis ossificans (TMO) is an ectopic ossifying lesion brought on by trauma to a bone or joint. Celecoxib is a selective non-steroidal anti-inflammatory drug frequently used to treat osteoarthritis. The aim of this study was to investigate the role and mechanism of celecoxib in osteogenesis and immunomodulation in an animal model of TMO.
Methods
A TMO model was established at the Achilles tendon of Sprague-Dawley (SD) rats and was treated with celecoxib. Before animal sacrifice, X-rays were used to examine the formation of new bone. The skin temperature of the affected side was also measured. The expression of bone morphogenetic protein-4 (BMP-4) in the Achilles tendon was assessed by Real-Time Quantitative PCR (RT-qPCR), Western blotting, and immunohistochemistry (IHC) methods, while the level of inflammatory factors in the serum was evaluated by enzyme-linked immunosorbent assay (ELISA).
Results
In a rat model of TMO treated with celecoxib (celecoxib group), swelling of the affected side was significantly reduced compared to the control group. Furthermore, the overall rate of bone formation in the celecoxib group was slower, the osteogenesis time was longer, the degree of ossification was less, and the tissue level of BMP-4 and serum levels of interleukin-2 (IL-2), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were reduced.
Conclusions
Celecoxib can effectively reduce the occurrence of TMO after Achilles tendon surgery in rats, along with reduced expression of BMP-4, IL-2, IL-6, and TNF-α, suggesting a possible link between its anti-osteogenic effect and modulation of these factors. This may provide a novel approach for the treatment of TMO in the clinic.
Förderung
- Project of Quanzhou Science & Technology Bureau
- Startup Fund for scientific research, Fujian Medical University
- Natural Science Foundation of Fujian Province
Zitieren
APA
Liu, M., Zeng, R., Shi, J., Xie, J., & Zhang, C. (2026). Celecoxib Attenuates Traumatic Myositis Ossificans by Decreasing Tissue BMP-4 Expression and Serum Levels of IL-2, IL-6, and TNF-α. International Journal of Pharmacology, 22(3). https://doi.org/10.31083/ijp47662
Vancouver
Liu M, Zeng R, Shi J, Xie J, Zhang C. Celecoxib Attenuates Traumatic Myositis Ossificans by Decreasing Tissue BMP-4 Expression and Serum Levels of IL-2, IL-6, and TNF-α. International Journal of Pharmacology. 2026;22(3). doi:10.31083/ijp47662
BibTeX
@article{Liu2026,
author = {Liu, Mingzhong and Zeng, Rongdong and Shi, Jianhui and Xie, Junjie and Zhang, Canhong},
title = {Celecoxib Attenuates Traumatic Myositis Ossificans by Decreasing Tissue BMP-4 Expression and Serum Levels of IL-2, IL-6, and TNF-α},
journal = {International Journal of Pharmacology},
year = {2026},
volume = {22},
number = {3},
doi = {10.31083/ijp47662}
}
EUVIMED